Pharmacy company Amber Specialty Pharmacy announced on Friday that it commenced administering the doses of new US FDA-approved infusion antibody treatment bamlanivimab (BAM) to long-term care facilities in Des Moines, Chicago, Buffalo, Phoenix and Dallas across the US to combat COVID-19 under a partnership with the US Department of Health and Human Services and the National Home Infusion Association.
The company added the purpose of the pilot programme is to expand access to a safe and effective treatment to the most vulnerable population across the country. The BAM pilot programme requires providers to be accredited and licensed to perform home infusions.
Bamlanivimab is a monoclonal antibody developed by Eli Lilly and received emergency FDA approval in November 2020. The infusion therapy is a tiered approach designed for high-risk patients who have the potential to develop severe complications from COVID-19.
While certain therapies and antiviral drugs used in hospitals inhibits the replication of the virus and shorten the course of the infection, BAM reportedly boosts the patient's own immune response to help fight the infection and prevent complications that would result in hospitalization, concluded the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT